Clinical trial · Observational
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER: Multicenter Retrospective Study (Real World Evidence - RWE)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A national, multicenter, non-randomized, retrospective, observational study (Real-World Evidence-RWE) aimed at analyzing clinical presentation profiles and demographic characteristics of patients with early urothelial bladder cancer (high-risk non-muscle invasive and localized muscle-invasive) treated with standard therapies in national cancer treatment reference centers within the last 6 years (between 2017 and 2022).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Muscle-invasive Bladder Cancer | — | UNRESOLVED | — |
| Non Muscle Invasive Bladder Cancer | — | UNRESOLVED | — |
| Urothelial Carcinoma | Urothelial Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Non-muscle-invasive bladder cancer or Muscle-invasive bladder cancer
- description
- Defined as: * T1 tumor and/or high-grade lesion (G3) and/or presence of CIS (Carcinoma in situ). * Multifocal relapsed tumor and with at least one large lesion (diameter ≥ 3 cm); Or: -Diagnosis of early muscle-invasive urothelial bladder carcinoma.
Primary outcomes (1)
- measure
- Clinical staging
- timeFrame
- At first diagnosis and over 6 years (Time of retrospective observational analysis of the study)
- description
- Description of the characteristics of the lesions at the initial diagnosis, performed by histopathology and imaging exams.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years old; * Diagnosis of high-risk non-muscle invasive urothelial carcinoma, defined as: * T1 tumor and/or high-grade lesion (G3) and/or presence of CIS. * Multifocal relapsed tumor and with at least one large lesion (diameter ≥ 3 cm); * Diagnosis of early muscle-invasive urothelial bladder carcinoma (cT2, cT3 or cT4a N0); * Consent to participate in the study. Exclusion Criteria: * Low-risk non-muscle invasive urothelial carcinoma (single lesion, pTa and low-grade); * Locally advanced muscle-invasive urothelial carcinoma (suspected lymph node impairment in staging imaging tests) or metastatic at diagnosis; * Bladder carcinoma with non-urothelial histology (adenocarcinoma, squamous-cell carcinoma or small cell carcinoma);
References
Publications (1)
- DERIVEDCastello Dias Carneiro AP, Batista EC, Gomes Bugano DD, Corradi RG, Panhoca R, Soler JA, Carvalhal E, Ponte de Souza AL, Motke B, Helber HA, Sampaio BDS, Monfardini F, Lamas Assis SR, Rodrigues Sant'Anna VA, Prado Dos Santos G, Lopes da Silva M, Duarte FM, Pereira M, Fagundes Moia DD, Soares RVP, Carneiro A, Perini GF, Rizzo LV, Maluf FC. Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study. JCO Glob Oncol. 2026 Apr;12(4):e2500324. doi: 10.1200/GO-25-00324. Epub 2026 Apr 29. PMID 42054609